

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Metaspacex Limited

(formerly known as Yield Go Holdings Ltd. 耀高控股有限公司)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1796)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2024

Reference is made to the annual report of Metaspacex Limited (the “**Company**”) for the year ended 31 March 2024 published on 26 July 2024 (the “**Annual Report**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Annual Report. This announcement provides supplemental information to the Annual Report and should be read in conjunction therewith.

SHARE OPTION SCHEME

In addition to the information provided in the Annual Report, the board (the “**Board**”) of directors of the Company (the “**Director(s)**”) wishes to provide to the shareholders (the “**Shareholder(s)**”) and potential investors of the Company with the following additional information in relation to the Share Option Scheme pursuant to the Rule 17.09 of the Listing Rules.

(1) Maximum number of options to any one individual

No option shall be granted to any eligible participant which, if exercised in full would result in the total number of the Shares issued and to be issued upon exercise of the options already granted and to be granted to such eligible participant (including options exercised, outstanding or cancelled under the Share Option Scheme and/or any other schemes of the Company) in any 12-month period up to the offer date exceeding 1% in aggregate of the Shares in issue on such offer date (the “**1% Individual Limit**”).

If the Board decides to grant options to an eligible participant that would exceed the 1% Individual Limit, such grant shall be subject to the approval of the Shareholders at a general meeting, at which that eligible participant and his close associates (or his associates, if the eligible participant is a core connected person) shall abstain from voting.

(2) Maximum number of options to substantial Shareholders and independent non-executive Directors

Where any grant of options to an independent non-executive Director or a substantial Shareholder (or any of their respective associates) would result in the Shares issued and to be issued upon exercise of all options granted and to be granted (including options exercised, outstanding or cancelled under the Share Option Scheme and/or any other schemes of the Company) to such person in the 12-month period up to and including the offer date:

- (i) representing in aggregate over 0.1% of the Shares in issue or such other percentage as may be from time to time provided under the Listing Rules; and
- (ii) having an aggregate value (based on the closing price of the Shares as quoted on the Stock Exchange on the offer date) in excess of HK\$5 million or such other sum as may be from time to time provided under the Listing Rules,

such grant of options must be approved by (i) the independent non-executive Directors; and (ii) the Shareholders in general meeting (with such grantee, his associates and all core connected persons of the Company abstaining from voting in favour of the resolution concerning such grant).

(3) Acceptance of option

An option shall be deemed to have been granted and accepted by the grantee and to have taken effect when the duplicate offer document constituting acceptance of the option duly signed by the grantee, together with a remittance or payment in favour of the Company of HK\$1.00 by way of consideration for the grant thereof is received by the Company on or before the prescribed acceptance date (being a date not later than 30 days after the offer date). Such remittance or payment shall in no circumstances be refundable.

(4) Vesting period

Unless the Directors otherwise determined and stated in the offer to the eligible participant, there is no minimum period for which an option granted under the Share Option Scheme must be held before it can be exercised.

(5) Exercise period

An option may be exercised in accordance with the terms of the Share Option Scheme after it is deemed to be granted and accepted, and at any time during a period to be determined by the Board in its absolute discretion, provided that no option may be exercised more than ten (10) years after the date of grant.

(6) Exercise price

The exercise price in relation to each option offered to an eligible participant shall, subject to the terms of the Share Option Scheme, be determined by the Board in its absolute discretion but in any event must be at least the higher of:

- (a) the official closing price of the Shares as stated in the daily quotation sheets of the Stock Exchange on the offer date;
- (b) the average of the official closing price of the Shares as stated in the daily quotation sheets of the Stock Exchange for the five (5) business days immediately preceding the offer date; and
- (c) the nominal value of a Share on the offer date.

(7) Remaining life of the Share Option Scheme

Subject to any early termination determined by the Board in accordance with the terms of the Share Option Scheme, the Share Option Scheme is valid and effective for a term of ten (10) years commencing on the listing date of the Company (i.e. 31 December 2018). Accordingly, as at the date of this announcement, the remaining life of the Share Option Scheme is approximately three and a half years.

The above additional information does not affect other information contained in the Annual Report. Save as disclosed above, all other information in the Annual Report remains unchanged.

By order of the Board
Metaspacex Limited
Kang Ruipeng
Chief Executive Officer and Executive Director

Hong Kong, 19 June 2025

As at the date of this announcement, the Board comprises Mr. Kang Ruipeng and Mr. Deng Houhua as executive Directors; and Mr. Cheng Pak Lam, Ms. Ya Li and Ms. Chen Yan as independent non-executive Directors.